Till sidans topp

Sidansvarig: Webbredaktion
Sidan uppdaterades: 2012-09-11 15:12

Tipsa en vän
Utskriftsversion

Plasma P-tau181 in Alzhei… - Göteborgs universitet Till startsida
Webbkarta
Till innehåll Läs mer om hur kakor används på gu.se

Plasma P-tau181 in Alzheimer's disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer's dementia

Artikel i vetenskaplig tidskrift
Författare S. Janelidze
N. Mattsson
S. Palmqvist
R. Smith
T. G. Beach
G. E. Serrano
X. Y. Chai
N. K. Proctor
U. Eichenlaub
Henrik Zetterberg
Kaj Blennow
E. M. Reiman
E. Stomrud
J. L. Dage
O. Hansson
Publicerad i Nature Medicine
Volym 26
Sidor 379-386
ISSN 1078-8956
Publiceringsår 2020
Publicerad vid Institutionen för neurovetenskap och fysiologi, sektionen för psykiatri och neurokemi
Sidor 379-386
Språk en
Länkar dx.doi.org/10.1038/s41591-020-0755-...
Ämnesord mild cognitive impairment, csf t-tau, cerebrospinal-fluid, clinical-diagnosis, national institute, supranuclear palsy, cross-validation, amyloid-beta, p-tau, f-18-av-1451, Biochemistry & Molecular Biology, Cell Biology, Research & Experimental, Medicine
Ämneskategorier Cellbiologi

Sammanfattning

Plasma phosphorylated tau181 (P-tau181) might be increased in Alzheimer's disease (AD), but its usefulness for differential diagnosis and prognosis is unclear. We studied plasma P-tau181 in three cohorts, with a total of 589 individuals, including cognitively unimpaired participants and patients with mild cognitive impairment (MCI), AD dementia and non-AD neurodegenerative diseases. Plasma P-tau181 was increased in preclinical AD and further increased at the MCI and dementia stages. It correlated with CSF P-tau181 and predicted positive Tau positron emission tomography (PET) scans (area under the curve (AUC) = 0.87-0.91 for different brain regions). Plasma P-tau181 differentiated AD dementia from non-AD neurodegenerative diseases with an accuracy similar to that of Tau PET and CSF P-tau181 (AUC = 0.94-0.98), and detected AD neuropathology in an autopsy-confirmed cohort. High plasma P-tau181 was associated with subsequent development of AD dementia in cognitively unimpaired and MCI subjects. In conclusion, plasma P-tau181 is a noninvasive diagnostic and prognostic biomarker of AD, which may be useful in clinical practice and trials. Plasma P-tau18 level increased with progression of Alzheimer's disease (AD) and differentiated AD dementia from other neurodegenerative diseases, supporting its further development as a blood-based biomarker for AD.

Sidansvarig: Webbredaktion|Sidan uppdaterades: 2012-09-11
Dela:

På Göteborgs universitet använder vi kakor (cookies) för att webbplatsen ska fungera på ett bra sätt för dig. Genom att surfa vidare godkänner du att vi använder kakor.  Vad är kakor?